Search Results - Erwin van Puijenbroek

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Optimizing asymmetric antibody purification: a semi-automated process and its digital integration

    Optimizing asymmetric antibody purification: a semi-automated process and its digital integration by Christophe Prince, Despoina Georgiadou, Manuela Machatti, Matthias Hermann, Erwin van Puijenbroek

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model

    The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model by Anthony Marinov, Haowei Wang, Sheldon Bastacky, Erwin van Puijenbroek, Thomas H. Schindler, Dario Speziale, Mario Perro, Christian Klein, Kevin M. Nickerson, Mark J. Shlomchik

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy

    High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy by Felicitas Rataj, Severin Jacobi, Stefan Stoiber, Florian Asang, Justyna Ogonek, Nicholas Tokarew, Bruno L. Cadilha, Erwin van Puijenbroek, Constanze Heise, Peter Duewell, Stefan Endres, Christian Klein, Sebastian Kobold

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab

    GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior <i>In Vivo</i> Efficacy Compared with Cetuximab by Christian A. Gerdes, Valeria Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine M. Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H. Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

    Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models by Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin van Puijenbroek, Sabine M. Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umaña, Gerhard Niederfellner, Marina Bacac, Christian Klein

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

    Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxic... by Ekkehard Mössner, Peter Brünker, Samuel Moser, Ursula Püntener, Carla Schmidt, Sylvia Herter, Roger Grau, Christian Gerdes, Adam Nopora, Erwin van Puijenbroek, Claudia Ferrara, Peter Sondermann, Christiane Jäger, Pamela Strein, Georg Fertig, Thomas Friess, Christine Schüll, Sabine Bauer, Joseph Dal Porto, Christopher Del Nagro, Karim Dabbagh, Martin J.S. Dyer, Sibrand Poppema, Christian Klein, Pablo Umaña

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

    Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy by Inja Waldhauer, Valeria Gonzalez‐Nicolini, Anne Freimoser–Grundschober, Tapan K. Nayak, Linda Fahrni, Ralf J. Hosse, Danny Gerrits, E.J. Geven, Johannes Sam, Sabine M. Lang, Esther Bommer, Virginie Steinhart, Elisabeth Husar, Sara Colombetti, Erwin van Puijenbroek, Markus Neubauer, J. Mark Cline, Pradeep Garg, Gregory O. Dugan, Federica Cavallo, Gonzalo Acuña, Jehad Charo, Volker Teichgräber, Stefan Evers, Otto C. Boerman, Marina Bacac, Ekkehard Moessner, Pablo Umaña, Christian Klein

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional I... by Christian Klein, Inja Waldhauer, Valeria Nicolini, Anne Freimoser–Grundschober, Tapan K. Nayak, Daniëlle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, M. Stihle, Sabine M. Lang, Michaele Roemmele, Thomas Höfer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina De Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus A.M.S. van Dongen, Ekkehard Moessner, Pablo Umaña

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: